What Is Retatrutide? Trial Data and FDA Status in 2026

August 9, 2026•Barba

Quick answer: Retatrutide (LY3437943) is an investigational, once-weekly injectable from Eli Lilly that activates three hormone receptors at once — GIP, GLP-1, and glucagon. It is not FDA-approved, and as of August 2026 Eli Lilly has not yet filed for approval. Four Phase 3 readouts have reported so far, with the pivotal obesity trial showing 28.3% average weight loss at 80 weeks.

What Is Retatrutide, Exactly?

Retatrutide is a triple hormone receptor agonist. Where earlier incretin drugs act on one or two metabolic pathways, retatrutide acts on three:

GLP-1 (glucagon-like peptide-1) — slows gastric emptying and reduces appetite
GIP (glucose-dependent insulinotropic polypeptide) — modulates insulin response and fat metabolism
Glucagon receptor — increases energy expenditure and hepatic fat breakdown

Receptor targets: single, dual, and triple agonists

What separates retatrutide from the approved incretin drugsGLP-1GIPGLUCAGONSemaglutideOzempic / Wegovy · approvedActiveTirzepatideMounjaro / Zepbound · approvedActiveActiveRetatrutideInvestigational · Phase 3ActiveActiveActive

Receptor coverage does not imply comparable efficacy or safety. Only semaglutide and tirzepatide are FDA-approved.

Receptor targets: single, dual, and triple agonists

What separates retatrutide from the approved incretin drugs

Receptor coverage does not imply comparable efficacy or safety. Only semaglutide and tirzepatide are FDA-approved.

That third target is the mechanistic reason retatrutide draws attention. Semaglutide and tirzepatide work largely by reducing intake; adding glucagon receptor activity brings energy expenditure into the equation, which is also why the liver-fat findings have been as notable as the weight numbers.

Every trial to date has used a once-weekly subcutaneous injection with stepwise dose escalation. That is a trial protocol, not a dosing instruction — there is no approved regimen because there is no approved product.

How Retatrutide Compares to Semaglutide and Tirzepatide

	Semaglutide	Tirzepatide	Retatrutide
Receptor targets	GLP-1	GLP-1 + GIP	GLP-1 + GIP + glucagon
Developer	Novo Nordisk	Eli Lilly	Eli Lilly
FDA status	Approved (Ozempic/Wegovy)	Approved (Mounjaro/Zepbound)	Investigational — Phase 3
Pivotal trial weight loss*	14.9% at 68 wks (STEP 1)	22.5% at 72 wks (SURMOUNT-1, 15 mg)	28.3% at 80 wks (TRIUMPH-1, 12 mg)

*Separate trials, different populations, different durations, different eras of trial design. These are not head-to-head results and should not be read as one. No published head-to-head trial of retatrutide against tirzepatide exists yet.

Because these three drugs are constantly compared on incomplete numbers, it is worth seeing how the three compare across mechanism, dosing, and cost rather than weight loss alone.

What the Clinical Trial Data Shows

Phase 2 (NEJM, 2023)

The trial that established retatrutide’s profile was a 338-participant randomized, placebo-controlled study in adults with obesity or overweight, led by Jastreboff and colleagues (NCT04881760), published in the New England Journal of Medicine. Participants received 1, 4, 8, or 12 mg weekly, or placebo, for 48 weeks.

Mean weight change at 48 weeks:

1 mg: −8.7%
4 mg: −17.1%
8 mg: −22.8%
12 mg: −24.2%
Placebo: −2.1%

At 12 mg, 60% of participants lost at least 15% of body weight. A companion Phase 2a substudy in participants with MASLD found liver fat reduced by more than 80% at higher doses, with most participants reaching normal liver-fat levels by 24 weeks.

Phase 3 obesity: TRIUMPH-1

TRIUMPH-1 (NCT05929066) is the pivotal obesity trial and the anchor of any eventual FDA filing. It randomized 2,339 adults with obesity or overweight plus at least one weight-related comorbidity, without diabetes, to 4, 9, or 12 mg or placebo. Lilly announced topline results on May 21, 2026; full data were presented at the ADA 86th Scientific Sessions on June 6, 2026.

Mean weight loss at the 80-week primary endpoint:

4 mg: −19.0%
9 mg: −25.9%
12 mg: −28.3%
Placebo: −2.2%

Retatrutide weight loss by dose — TRIUMPH-1

Mean percentage of body weight lost at the 80-week primary endpoint (n=2,339)

Source: Eli Lilly TRIUMPH-1 topline results, 21 May 2026; full data presented at the ADA 86th Scientific Sessions, 6 June 2026. Retatrutide is investigational and has not been approved by the FDA.

Retatrutide weight loss by dose — TRIUMPH-1

Mean percentage of body weight lost at the 80-week primary endpoint (n=2,339)0%10%20%30%2.2%Placebo19.0%4 mg25.9%9 mg28.3%12 mgDoses shownare trialprotocol only

Source: Eli Lilly TRIUMPH-1 topline results, 21 May 2026; full data presented at the ADA 86th Scientific Sessions, 6 June 2026. Retatrutide is investigational and has not been approved by the FDA.

At 12 mg, 45.3% of participants lost at least 30% of body weight and 65.3% finished with a BMI below 30.

A prespecified blinded extension followed 532 participants with baseline BMI ≥35 out to 104 weeks. In that subgroup, the higher doses reached up to 30.3% mean weight loss. This is the figure most often quoted without its context — it describes a severe-obesity extension cohort, not the full trial population, and treating it as a headline number for the drug overstates what was measured.

On tolerability, the 4 mg arm is the quietly interesting result: discontinuation due to adverse events was 4.1%, slightly below the 4.9% placebo rate, which points to the escalation schedule rather than the drug itself driving most dropouts. Dysesthesia — an abnormal skin sensation seen across retatrutide trials — occurred in 12.5% at 12 mg, lower than the 20.9% reported in TRIUMPH-4. The dysesthesia signal is the one most likely to shape the eventual label, and it is worth reviewing the reported side effect data dose by dose.

For the endpoint-by-endpoint breakdown, including the secondary outcomes not covered here, see the complete TRIUMPH-1 results analysis.

Phase 3 diabetes: TRANSCEND-T2D-1

TRANSCEND-T2D-1 (NCT06354660) belongs to a separate, diabetes-specific program — not the TRIUMPH obesity program. It randomized 537 adults with type 2 diabetes inadequately controlled by diet and exercise to 4, 9, or 12 mg or placebo over 40 weeks. Topline results came in March 2026; the full paper was published in The Lancet in June 2026.

HbA1c fell 1.69, 1.86, and 1.94 percentage points at 4, 9, and 12 mg respectively, against 0.81 points on placebo. Weight loss reached 16.8%. One caveat the authors raise themselves: the population was largely medication-naïve, which limits how far the findings generalize to people already on antihyperglycaemic drugs or insulin.

Is Retatrutide FDA-Approved?

No. As of August 2026, retatrutide is not approved for any indication anywhere, and no application has been filed. That distinction matters: media coverage frequently discusses a submission window, but a projected filing date is not a filing.

Eli Lilly announced on 23 July 2026 that it will submit a Biologics License Application in Q1 2027 — a shift from the Q4 2026 filing previously expected. Retatrutide is regulated as a biologic rather than a small-molecule drug, which is why the submission is a BLA and not an NDA. From there, standard FDA review runs about 10 months from filing acceptance, putting a decision in late 2027 or the first half of 2028 and commercial availability in 2028. Priority review would move that up roughly four months. None of this is guaranteed — the FDA can request additional data, narrow the indication, or set different terms entirely, and open questions like the dysesthesia signal and final BMI/comorbidity criteria will be part of that review.

Because this timeline shifts with each readout, the current FDA approval timeline is tracked separately and updated as milestones land.Retatrutide development and regulatory timeline

Confirmed milestones in blue; projected dates in greyJun 2023Phase 2NEJMDec 2025TRIUMPH-4Mar 2026TRANSCEND-T2D-1May 2026TRIUMPH-1pivotalQ4 2026NDA filingLate 2027FDA decision2028LaunchConfirmedProjected — not announced by Eli Lilly

No NDA has been filed as of August 2026. Projected dates reflect standard FDA review timelines and industry expectation, not company guidance.

Compounding

There is no legal compounding pathway for retatrutide. Because it is not an FDA-approved drug and has no USP monograph, it falls outside sections 503A and 503B of the federal statute that permit pharmacy compounding. The FDA has acted on this directly — a September 2025 warning letter cited compounded retatrutide products as unapproved new drugs with no approved applications on file.

Why “Retatrutide” Is Sold Online — and What That Actually Means

Search for retatrutide and you will find vendors selling vials labeled as research peptides. Being plain about it: these are not FDA-approved products, they are not manufactured under the controls that apply to prescription drugs, and there is no regulatory body verifying identity, purity, or concentration of what is in the vial. Independent testing of the unregulated peptide market has repeatedly found mislabeled content and inconsistent dosing. The “research use only” label is a legal posture, not a quality assurance. There are legitimate routes to access it, and this is not one of them.

Two legitimate routes exist today: enrolling in an active clinical trial (listings are searchable on ClinicalTrials.gov) or waiting for approval, after which retatrutide would be prescribed and dispensed like any other medication, with an established dosing protocol and clinician oversight behind it.

What Happens Next

The near-term milestones worth tracking:

TRIUMPH-2 and TRIUMPH-3 readouts, expected through late 2026
Whether Lilly files the NDA on the Q4 2026 timeline it has signaled
FDA filing acceptance and the assigned PDUFA date
Which indications and patient populations end up in any approved label
UK availability and MHRA status, which follows a separate regulatory track

If you are weighing obesity or diabetes treatment now, the practical conversation is about approved options — the drugs that already have safety databases, dosing guidance, and prescribers behind them. A licensed clinician is the right person to have that conversation with.

This page covers retatrutide’s status at a high level. For the trial-by-trial detail, comparisons with approved drugs, and the regulatory tracker, browse the full retatrutide research library.

Frequently Asked Questions

Is retatrutide the same as tirzepatide?
No. Tirzepatide activates two receptors, GLP-1 and GIP. Retatrutide adds a third, the glucagon receptor. Both are Eli Lilly drugs, but tirzepatide is approved and retatrutide is not.

Can I buy retatrutide right now?
Not as an approved medication — none exists. Vials sold online as research peptides are unregulated, unverified, and not approved or intended for human use.

When will retatrutide be FDA-approved?
No date exists. Lilly plans to submit a Biologics License Application in Q1 2027, which would put an FDA decision in late 2027 or the first half of 2028, and availability in 2028.

How much weight did trial participants lose?
28.3% on average at 80 weeks on the 12 mg dose in TRIUMPH-1, and 19.0% at 4 mg. A severe-obesity extension cohort reached up to 30.3% at 104 weeks. Results vary substantially by dose, population, and duration.

Is retatrutide safe?
Its safety profile is still being characterized, and the FDA has not reviewed it. Trials report gastrointestinal effects typical of this drug class, plus dose-related dysesthesia. This is not medical advice — safety questions about any treatment belong with a licensed clinician.

Why does retatrutide cause more weight loss than GLP-1 drugs?
The working explanation is the glucagon receptor component, which raises energy expenditure rather than only suppressing appetite. This is a mechanistic interpretation supported by the trial data, not a settled finding.

This article is for general informational purposes and is not medical advice. Retatrutide is investigational and has not been approved by the FDA for any use. Consult a licensed healthcare provider about obesity or diabetes treatment options.

Sources

Jastreboff AM, Kaplan LM, Frías JP, et al. “Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial.” N Engl J Med. 2023;389:514–526.
Bajaj HS, et al. “Efficacy and safety of retatrutide… in people with type 2 diabetes (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial.” The Lancet. 2026. doi:10.1016/S0140-6736(26)00967-0
“Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.” Nat Med. 2024.
Giblin K, Kaplan LM, Somers VK, et al. “Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials.” Diabetes Obes Metab. 2026;28(1):83–93.
Eli Lilly. “Lilly’s triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial.” May 21, 2026.
Eli Lilly. ADA 86th Scientific Sessions data announcement, June 6, 2026.
ClinicalTrials.gov: NCT04881760, NCT05929066, NCT06354660.